CytomX Therapeutics Conference Call Summary Company Overview - **Company**: CytomX Therapeutics (NasdaqGS:CTMX) - **Focus**: Development of masked biologics technology, specifically targeting cancer therapies [2][3] Key Industry Insights - **Technology**: CytomX has pioneered the field of masked biologics, allowing for targeted drug delivery to tumor cells while minimizing effects on healthy tissues [2][3] - **Clinical Programs**: The company is currently focused on two clinical programs, with the lead program being a masked EpCAM antibody-drug conjugate (ADC) [3][4] Core Product Insights - **Lead Product**: CX-2051, a masked ADC targeting EpCAM, which is highly expressed in various solid tumors, particularly colorectal cancer (CRC) [5][6] - **Target Rationale**: EpCAM is a compelling target due to its high expression in solid tumors, but previous attempts to target it have faced toxicity issues. CytomX believes its masking technology can mitigate these toxicities [5][6][7] Clinical Data Highlights - **Colorectal Cancer Statistics**: CRC has 1.9 million cases globally and is the second leading cause of cancer death, with a five-year survival rate of only 13% in metastatic cases [12] - **Phase 1 Data**: In a difficult-to-treat patient population (average of four prior therapies), CX-2051 showed a 28% objective response rate and 94% disease control rate, with a progression-free survival (PFS) of 5.8 months [14][19] - **Safety Profile**: The drug did not exhibit classic EpCAM-related toxicities such as pancreatitis or liver toxicity. The main adverse effect observed was grade 3 diarrhea in 21% of patients [15][16] Future Development Plans - **Expansion of Clinical Trials**: CytomX plans to expand the enrollment to approximately 100 patients across three active doses (7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg) to better understand efficacy and safety [19][20] - **Regulatory Pathway**: The company aims to discuss potential registrational studies with the FDA by mid-2027, focusing on late-line CRC treatment [37][38] Competitive Landscape - **Market Position**: CytomX believes it has a strong competitive position in the ADC space for CRC, with a compelling drug profile compared to other ADCs targeting CRC [46][47] - **Other ADCs**: Competitors include Merck's CEACAM5 ADC and AbbVie's cMet ADC, but CytomX asserts that its drug has broader applicability due to the widespread expression of EpCAM [46][47] Combination Therapy Strategy - **Initial Combinations**: The company plans to start combination studies with bevacizumab and is considering other combinations to enhance treatment efficacy and expand market opportunities [49][50] - **Long-term Vision**: CytomX aims to replace traditional chemotherapy regimens, particularly irinotecan, with its ADC in earlier treatment lines [41][42] Additional Product Insights - **Other Asset**: CytomX is also developing a second product candidate, an interferon alpha-2b therapy for late-line melanoma, which is expected to be combined with KEYTRUDA [53] Conclusion - CytomX Therapeutics is positioned to address significant unmet needs in cancer treatment, particularly in CRC, with its innovative masked biologics technology and promising clinical data. The company is focused on expanding its clinical trials and exploring combination therapies to enhance treatment outcomes.

Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing novel conditionally activated, masked biologics aimed at localizing treatment to the tumor microenvironment [3] - The company utilizes its PROBODY therapeutic platform to create safer and more effective cancer therapies, with a pipeline that includes antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators [3] Clinical Pipeline - Current clinical-stage candidates include CX-2051, a masked ADC targeting epithelial cell adhesion molecule (EpCAM) with a topoisomerase-1 inhibitor payload, and CX-801, a masked interferon alpha-2b PROBODY cytokine [3] - CX-2051 has potential applications in various EpCAM-expressing epithelial cancers, including colorectal cancer (CRC), and was developed in collaboration with ImmunoGen [3] - CX-801 is designed for broad applicability in both immuno-oncology sensitive and insensitive tumors [3] Strategic Collaborations - CytomX has established partnerships with leading companies in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3] Upcoming Events - Management will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, and the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025 [2] - A live webcast of the presentations will be available on CytomX's website, and management will hold one-on-one meetings with registered investors [2]

Core Insights - CytomX Therapeutics is advancing its CX-2051 Phase 1 study for colorectal cancer (CRC) with 73 patients enrolled and aims to provide a data update in Q1 2026 [1][2][6] - Patient safety is prioritized as the study continues with dosing across all expansion doses [2][6] Company Overview - CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing conditionally activated, masked biologics for cancer treatment [4] - The company utilizes its PROBODY therapeutic platform to create localized therapies, including antibody-drug conjugates (ADCs) and immune modulators [4] - Current clinical-stage pipeline includes CX-2051, a masked ADC targeting epithelial cell adhesion molecule (EpCAM), and CX-801, a masked interferon alpha-2b PROBODY cytokine [4] CX-2051 Program Status - The CX-2051 study has enrolled approximately 20 patients at each of the three expansion doses: 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg, administered every three weeks [6] - A serious adverse event (Grade 5 treatment-related acute kidney injury) was reported, but the study continues with support from the Safety Review Committee [6] Strategic Collaborations - CytomX has established partnerships with leading oncology companies, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [4]

Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing conditionally activated, masked biologics localized to the tumor microenvironment [3] - The company utilizes its PROBODY® therapeutic platform to create safer and more effective cancer therapies [3] - CytomX's pipeline includes therapeutic candidates such as CX-2051 and CX-801, with CX-2051 being a masked, conditionally activated ADC targeting epithelial cell adhesion molecule (EpCAM) [3] Financial Results Announcement - CytomX will report its first quarter financial results on May 12, 2025, before the U.S. markets open [1] - A conference call and webcast will follow the announcement at 8:00 a.m. ET / 5:00 a.m. PT [1] Strategic Collaborations - The company has established collaborations with major oncology leaders including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3]